articleThe LancetOct 1, 2005GREEN OA

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

JDJohn DormandyBCB CharbonnelDED.J.A. EcklandEEErland ErdmannMMMassimo Massi‐Benedetti

St George's Hospital · University of Cologne · +24 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

4,126
total citations
FWCI
136.46
Percentile
100%
References
19
Citations per year

Authors

30

Topics & keywords

Topics
Keywords
  • Medicine
  • Pioglitazone
  • Macrovascular disease
  • Internal medicine
  • Myocardial infarction
  • Clinical endpoint
  • Type 2 diabetes
  • Stroke (engine)
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.